Trexquant Investment LP Invests $2.37 Million in Krystal Biotech, Inc. $KRYS

Key Points

• Trexquant Investment LP made a significant investment of approximately $2.37 million in Krystal Biotech, acquiring 13,122 shares during the first quarter.
• Insider Suma Krishnan sold 13,435 shares valued at over $2 million, decreasing their ownership by 0.92%.
• Analysts generally rate Krystal Biotech a "Moderate Buy" with a consensus target price of $210.38, despite some reductions in individual price targets.

Trexquant Investment LP purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,122 shares of the company's stock, valued at approximately $2,366,000.

A number of other large investors have also recently added to or reduced their stakes in KRYS. Fifth Third Bancorp raised its position in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after purchasing an additional 432 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $229,000. M&T Bank Corp purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $667,000. Finally, Bryce Point Capital LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $790,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KRYS shares. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Friday, August 22nd. Bank of America reduced their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Chardan Capital reduced their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $210.38.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at $216,924,382.80. This represents a 0.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 49,800 shares of company stock worth $7,487,943. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Trading Up 0.8%

NASDAQ:KRYS opened at $150.20 on Thursday. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of 30.53 and a beta of 0.66. The company's 50-day moving average is $146.28 and its two-hundred day moving average is $154.21. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.